Cancer immunotherapy drives implementation science in oncology

Area of Science:

• Immunology
• Oncology
• Cancer Research

Background:

• Cancer immunotherapy has evolved from modest progress to significant clinical success, particularly in hematological cancers.
• Recent advancements have expanded immunotherapy's role in treating solid tumors, shifting focus from cancer cells to a comprehensive tumor biology.
• Research and development (R&D) now integrates tumor stroma, immune cells, vasculature, and host systemic factors into a broader understanding of cancer progression.

Discussion:

• The field of immunology has fundamentally broadened the scope of cancer research beyond a cancer-cell-centered view.
• Current R&D investigates diverse mechanisms driving tumor growth, including cancer cells, tumor stroma, and systemic host factors.
• Therapeutic strategies are increasingly focused on harnessing the immune system's potential to counteract tumor growth.

Key Insights:

• Immunotherapy has achieved considerable clinical success in hematological cancers and is now pivotal for solid tumors.
• A comprehensive vision of tumor biology, integrating various cellular and systemic factors, guides current R&D.
• Enhancing specific immune mechanisms holds prime potential for clinical benefit in cancer patients.

Outlook:

• This special issue focuses on immunotherapeutics, particularly cancer vaccination and combination therapies.
• Future R&D aims to provide updated insights into the rapidly advancing field of cancer immunotherapy.
• The integration of immunological approaches represents a booming area in cancer treatment development.